To use all functions of this page, please activate cookies in your browser.
My watch list
my.chemeurope.com
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
ExforgeExforge® is the brand name of an oral antihypertensive medication which combines two antihypertensive agents in a film-coated tablet. It contains amlodipine, a calcium channel blocker, and valsartan, an angiotensin-2 receptor antagonist (ARB or A2A). The patent is held by Novartis Pharmaceuticals. Product highlightExforge is available in different dose preparations: 5mg/160mg, 10mg/160mg,5mg/320mg and 10/3200mg's of amlodipine and valsartan respectively.
Categories: Calcium channel blockers | Angiotensin II receptor antagonists |
| This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Exforge". A list of authors is available in Wikipedia. |
Last viewed
- A way to synthesize drugs from renewable precursors
- Packed Chlorine Ltd - Runcorn, Reino Unido
- Construction of Oxea’s new specialty derivatives plant in China well on track
- ERKOMAT OY - Kotka, Finlândia
- The rise of carbon dioxide as a renewable carbon feedstock - More than 1.3 million tonnes capacity for CO2-based products already exist and are expected to at least quadruple by 2030
